Top Abstract Purchase Related
Home
>
Node
>
Subnode

Treatment of nonalcogolic fatty disease of liver

Antelava, N.A.; Gongadze, M.V.; Okudzhava, M.V.; Pachkoriia, K.Z.; Gogolauri, M.I.

Georgian Medical News 2012(208-209): 24-30

2012

ISSN/ISBN: 1512-0112
PMID: 22899407
Document Number: 658023
The experimental and clinical data concerning of treatment of nonalcogolic fatty liver disease (NAFLD) are summarized and analyzed in the review. Some aspects of pathogenetic pharmacotherapy of NAFLD have been discussed (correction of insulin resistance, obesity, dislipidemia, oxidative stress, hepatoprotectors, restoration of intestine microbiosis, replacement hormonal, syndrome and antihypertensive drugs). Medical and non - medical methods of treatment is compared. It is concluded that further study to improve methods of prevention and treatment of NAFLD are required.

Document emailed within 1 workday
Secure & encrypted payments

Jin, H-Bin.; Gu, Z-Ying.; Yu, C-Hui.; Li, Y-Ming. 2005: Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients Hepatobiliary and Pancreatic Diseases International: Hbpd Int 4(3): 389-392
Grigor'eva, I.N. 2011: UDCA in the treatment of nonalcoholic fatty liver disease Eksperimental'naia i Klinicheskaia Gastroenterologiia 11: 79-85
Grigor'eva, I.N. 2011: UDCA in the treatment of nonalcoholic fatty liver disease Eksperimental'naia i Klinicheskaia Gastroenterologiia 9: 125-131
Heebøll, S.; Kazankov, K.; Poulsen, M.K.ær.; Vilstrup, H.; Grønbæk, H. 2012: Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis Ugeskrift for Laeger 174(8): 488-490
Podymova, S.D. 2016: [The Modern View on Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease Eksperimental'naia i Klinicheskaia Gastroenterologiia 5: 74-82
Zhu, Q.-q.; Lou, D.-j.; Si, X.-w.; Guan, L.-l.; You, Q.-y.; Yu, Z.-m.; Zhang, A.-z.; Li, D. 2010: Serum omega-3 polyunsaturated fatty acid and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease Zhonghua Nei Ke Za Zhi 49(4): 305-308
Aller, R.; De Luis, D.A.; Fernandez, L.; Calle, F.; Velayos, B.; Izaola, O.; Gonzalez Sagrado, M.; Conde, R.; Gonzalez, J.M. 2009: Influence of Ala54Thr polymorphism of fatty acid-binding protein 2 on histological alterations and insulin resistance of non alcoholic fatty liver disease European Review for Medical and Pharmacological Sciences 13(5): 357-364
Fukuhara, T.; Hyogo, H.; Ochi, H.; Fujino, H.; Kan, H.; Naeshiro, N.; Honda, Y.; Miyaki, D.; Kawaoka, T.; Tsuge, M.; Hiramatsu, A.; Imamura, M.; Kawakami, Y.; Aikata, H.; Chayama, K. 2014: Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus Hepato-Gastroenterology 61(130): 323-328
Karim, M.R.; Ahmed, H.; Paul, R.K.; Chowdhury, M.; Alam, M.S.; Saha, A. 2016: Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients Mymensingh Medical Journal: Mmj 25(2): 198-204
Chen, J.; Zheng, R.-D.; Xu, C.-R.; Wu, W.-P. 2009: Expression and significance of liver X receptor-alpha in nonalcoholic fatty liver disease in rats Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 23(4): 265-268
Chen, L.-l.; Deng, X.-q.; Li, N.-x. 2007: Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats Zhonghua Yi Xue Za Zhi 87(20): 1434-1437
Mori, M.; Yokoyama, M.; Yokoyama, S.; Onoe, T. 1974: Electron microscopic study of the development of fatty liver. II. Fatty liver associated with low dietary intake of proteins Hokkaido Journal of Medical Science 49(2): 161-162
Vogelberg, K.H.; Gisbertz, K.H.; Moschinsky, D.; Both, A.; Bostroem, B.; Kübler, W.; Gries, F.A. 1974: Effect of insulin on fatty acid metabolism in the liver in endogenous hypertriglyceridemia. Findings on the uptake of free fatty acids and ketone body production of the liver Verhandlungen der Deutschen Gesellschaft für Innere Medizin 80: 1264-1266
Sdiri, W.; Romdhane, H.; Mbarek, D.; Ben Abdallah, H.; Longo, S.; Abdelli, M.N.; Boujnah, M.R. 2013: Non alcoholic fatty liver disease: a new risk factor for cardiovascular disease? La Tunisie Medicale 91(3): 171-174
Semmler, F. 1977: Treatment of liver diseases, especially of fatty liver with betaine citrate Therapie der Gegenwart 116(11): 2113-2124
Yoshihara, H.; Sato, N.; Kubota, S.; Inoue, A.; Matsumura, T.; Hayashi, N.; Kawano, S.; Kamada, T. 1985: Serum holo and apo type activity of mitochondrial GOT in patients with alcoholic liver disease--with special reference to alcoholic fatty liver Arukoru Kenkyu to Yakubutsu Izon 20(2): 166-174
Dasarathy, J.; Allampati, S.; Alexander, C.; McCullough, A. 2016: Non-alcoholic fatty liver disease: What's in our arsenal? Journal of Family Practice 65(4): 239-244
Bedossa, P. 2012: Lesions in nanolcoholic fatty liver disease La Revue du Praticien 62(10): 1419
Fan, J.-G.; Farrell, G.C. 2009: Epidemiology of non-alcoholic fatty liver disease in China Journal of Hepatology 50(1): 204-210
Björklund, J.; Laursen, T.L.; Kazankov, K.; Thomsen, K.L.; Hamilton-Dutoit, S.; Stenbøg, E.; Grønbæk, H. 2017: Non-alcoholic fatty liver disease in children and adolescents Ugeskrift for Laeger 179(27)